Collectively, these clinical sample data also verified that the expressions of METTL3 and IGF2BP3 were positively correlated with PD-L1 and indicated that PD-L1 could be a potential downstream target of the METTL3/IGF2BP3 axis in breast cancer. This evidence concerns the gene METTL3 and breast cancer.